Test Price
2,800 AED✅ Home Collection Available
EYA4 Gene Dilated Cardiomyopathy Type 1J Genetic Test in UAE – 2800 AED
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity and specificity for pathogenic EYA4 variants via validated NGS workflow.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across Dubai and all UAE emirates.
- Post-Test Physician Consultation: Telephonic medical consultation included with every genetic report for comprehensive result interpretation.
- Insurance Verification: Direct coverage check via WhatsApp at +971 54 548 8731 prior to scheduling.
Test Overview & Methodology
This comprehensive next-generation sequencing (NGS) test interrogates the full coding region and splice-site boundaries of the EYA4 gene to detect pathogenic and likely pathogenic variants responsible for dilated cardiomyopathy type 1J (CMD1J). The analysis enables precise molecular diagnosis for at-risk individuals, cascade screening for family members, and informed clinical surveillance planning.
Methodology employs whole-exon capture NGS with concurrent deletion and duplication (CNV) analysis on the Illumina platform, achieving a mean depth of coverage exceeding 100x across all targeted regions. All clinically significant findings are confirmed by orthogonal Sanger sequencing prior to report release.
| Feature | Our EYA4 NGS Test | Closest Alternative (Standard Panel) |
|---|---|---|
| Diagnostic Precision | 99.9% Sensitivity & Specificity for EYA4 pathogenic variants | Varies; may miss deep intronic or copy number variants |
| Methodology | Full-exon NGS with deletion/duplication analysis | Targeted Sanger sequencing or limited gene panel |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “A family history of dilated cardiomyopathy understandably raises significant concern. This EYA4 gene test provides essential molecular clarity, but results must be correlated with clinical echocardiographic findings, electrocardiogram data, and a three-generation pedigree analysis. I strongly advocate pre-test and post-test genetic counseling to ensure patients comprehend the implications for themselves and their relatives. This test is a powerful tool within a comprehensive cardiac risk assessment framework.”
Advisory Notice – Medication Continuity
Important: Do not discontinue, alter, or pause any prescribed cardiac medication, including beta-blockers, ACE inhibitors, diuretics, or anticoagulants, without direct consultation with your treating physician. Genetic testing results do not replace ongoing clinical management or medication adjustments supervised by a cardiologist.
Safety Exclusion Criteria & Emergency Red Flags
- This genetic test is not intended for acute cardiac emergencies or diagnosis of decompensated heart failure.
- If you experience sudden chest pain, severe shortness of breath, syncope, or rapid irregular heartbeat, seek immediate emergency medical attention at the nearest hospital.
- Not suitable for minors without authorized guardian consent as specified under Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Patients with unstable or decompensated heart failure must not undergo elective genetic blood draw without written physician clearance.
Patient FAQ & Clinical Guidance
1. What is dilated cardiomyopathy type 1J and why is genetic testing important?
Dilated cardiomyopathy type 1J is an inherited form of heart muscle disease caused by pathogenic variants in the EYA4 gene. It leads to progressive enlargement and weakening of the left ventricle. Genetic testing confirms the molecular diagnosis, enables early intervention with guideline-directed medical therapy, and identifies at-risk family members for cascade screening and preventive surveillance.
2. Who should consider this EYA4 genetic test?
Individuals with a strong family history of dilated cardiomyopathy, unexplained heart failure diagnosed before age 50, or a personal or family history of sudden cardiac death should undergo this test. It is also recommended for first-degree relatives of a confirmed EYA4 variant carrier to determine their own risk status.
3. How is the sample collected and what is the turnaround time?
A standard peripheral blood sample is collected via venipuncture. VIP mobile phlebotomy and temperature-controlled cold-chain home collection are available daily from 8 AM to 11 PM. Alternatively, you may visit any DNA Labs UAE facility. Results are typically reported within 3 to 4 weeks from sample receipt at the laboratory.
4. Does health insurance cover the cost of this test?
Coverage depends on your individual policy and insurer. DNA Labs UAE provides direct billing verification via WhatsApp at +971 54 548 8731 to confirm your eligibility and out-of-pocket liability before the test is performed.
UAE Regulatory & Data Privacy Adherence
Data Protection & Confidentiality: All genetic data and personal health information are processed, stored, and transmitted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. No genetic information is shared with third parties without explicit written patient consent.
Clinical Safety & Consent: All testing procedures adhere to the standards set forth in Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring patient autonomy through informed consent and strict oversight of all diagnostic protocols.
Clinical & Logistical Metadata
| Test Name | EYA4 Gene Dilated Cardiomyopathy Type 1J Genetic Test – NGS Full-Exon Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA tube); DNA extraction from blood; alternative FTA card acceptable. VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM. |
| Methodology Used | Next-Generation Sequencing (NGS) – whole-exon capture with CNV analysis via Illumina platform; Sanger confirmation of clinically significant variants. |
| ICD-10-CM Code | I42.0 |
| LOINC Code | 94827-1 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians